Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412644 · ClinicalTrials.gov registry record · Phase 4
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
A Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT02412644 is a Phase 4 study that has completed, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 29 participants.
The verdict
NCT02412644, a Phase 4 study, has completed, sponsored by Psoriasis Treatment Center of Central New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
Interventions
- DRUG apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-05-28 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412644
The ClinicalTrials.gov registry entry for NCT02412644 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apremilast is the first listed.
NCT02412644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02412644 about?
NCT02412644 is a clinical study titled "Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis". 12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
What is the current status of trial NCT02412644?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2015-05-28. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02412644?
The interventions under investigation include: apremilast (DRUG).
Who is sponsoring clinical trial NCT02412644?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.